

# Transaction Prices for Antiretroviral Medicines and HIV Diagnostics from 2004 to September 2008



A summary report from the Global  
Price Reporting Mechanism  
October 2008

## Contents

Abbreviations . . . . .	5
Table 1 : Median transaction price of <i>first-line</i> ARV medicines for adult treatment per patient per year (US\$/ppy) at a WHO recommended adult defined daily dose (DDD) . . . . .	6
Table 2: Median transaction price of <i>second-line</i> ARV medicines (US\$/ppy) for adult treatment at a WHO recommended adult DDD . . . . .	9
Table 3: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment ( <i>infant weighing 5 kg</i> ) at a WHO recommended paediatric DDD. . . . .	12
Table 4: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment ( <i>infant weighing 10 kg</i> ) at a WHO recommended paediatric DDD . . . . .	15
Table 5: Median transaction price (US\$) of smallest unit of <i>rapid tests</i> . . . . .	18
Table 6: Median transaction price of <i>ELISA and confirmatory tests</i> in 2007 and 2008 (US\$) . . . . .	19
Fig. 1a: The price trend for the most commonly used <i>first-line regimens in low-income countries (LIC)</i> for adult patients. . . . .	20
Fig. 1b: The price trend for the most commonly used <i>first-line regimens in lower middle-income countries (LMIC)</i> for adult patients. . . . .	20
Fig. 1c: The price trend for the most commonly used <i>first-line regimens in upper middle-income countries (UMIC)</i> for adult patients. . . . .	21
Fig. 2a: The price trend for the most commonly used <i>second-line regimens in low-income countries (LIC)</i> for adult patients. . . . .	22
Fig. 2b: The price trend for the most commonly used <i>second-line regimens in lower middle-income countries (LMIC)</i> for adult patients . . . . .	22
Fig. 2c: The price trend for the most commonly used <i>second-line regimens in upper middle-income countries (UMIC)</i> for adult patients. . . . .	23
Fig. 3a: The price trend for the most commonly used <i>first-line regimens</i> for paediatric patients ( <i>infant of 5 kg</i> ). . . . .	24
Fig. 3b: The price trend for the most commonly used <i>second-line regimens</i> for paediatric patients ( <i>infant of 5 kg</i> ). . . . .	24
Fig. 4a: The price trend for the most commonly used <i>first-line regimens</i> for paediatric patients ( <i>infant of 10 kg</i> ). . . . .	25
Fig. 4b: The price trend for the most commonly used <i>second-line regimens</i> for paediatric patients ( <i>infant of 10 kg</i> ). . . . .	25
Figure 5: Number of HIV rapid test (2004 - 2007) (millions) . . . . .	26
Discussion . . . . .	26
Formulations for adult first-line regimens.....	26
Formulations for adult second-line regimens .....	26
Paediatric formulations .....	27
HIV diagnostics.....	28
Conclusions .....	29
References . . . . .	30

The Global Price Reporting Mechanism (GPRM) contains information on transaction prices and quantities of ARVs and HIV diagnostics purchased by HIV/AIDS programmes in low-income countries\*, lower middle-income countries† and upper middle-income countries‡. Prices are determined using the World Bank Atlas calculation method<sup>1,2</sup>. The GPRM complements reports of price quotes from pharmaceutical companies<sup>3,4,5</sup> as well as smaller sets of transaction prices published by other sources<sup>6,7,8,§</sup>.

The report features the transactions data from 2004 up to the end of September 2008 and is based on communications received by 10 October 2008. All transaction data have been compiled and stored in a searchable database by the AIDS Medicines & Diagnostics Service (AMDS) of WHO HIV/AIDS Department and are available at <http://www.who.int/hiv/amds/price/hdd/>.

The information provided in this report reflects transactions of:

- twenty-eight formulations commonly used for adult HIV treatment
- thirty-three formulations for paediatric treatment recommended by WHO for the first and second-line regimens<sup>9,10,11</sup>
- twenty HIV serology tests (fifteen rapid, six ELISA, and four confirmatory) purchased by low-income, lower middle-income and upper-middle-income countries in 2007 and 2008.

The GPRM also contains data for less frequently used ARV formulations, medicine for opportunistic infections, medicines for malaria and tuberculosis treatment, and other health commodities related to the treatment of HIV, TB and malaria. However, this summary report does not include those data due to limited transactions volumes for the relevant commodities.

\* countries with a gross national income (GNI) per capita of US\$ 935 or less

† countries with a GNI per capita between US\$ 936 and US\$ 3,705

‡ countries with a GNI per capita between US\$ 3,706 and US\$ 11,455

§ The transaction data in the GPRM are provided by the following organizations: the Clinton Foundation; HIV/AIDS Initiative/UNITAID; the Global Fund to Fight AIDS, Tuberculosis, and Malaria; the International Dispensary Association; USAID/deliver (former John Snow Inc./deliver); Management Sciences for Health; Missionpharma; Supply Chain Management System; the United Nations Children's Fund; and the World Health Organization's Contracting and Procurement Service.

The prices in this report are reported as median prices with the inter-quartile range (IQR)\*\*. The combination of the median value and the IQR, rather than the mean  $\pm$  standard deviation, was selected to present the data in view of an asymmetrical distribution nature of the data. For the interpretation and use of the data in this report it is important to note that:

1) All prices are shown in US Dollars (US\$) per patient per year of a defined daily dose of each medicine for adults or children.

2) Taxes, tariffs, and/or International Commercial Terms (INCOTERMS: cost or condition of transport, insurance, etc.) are not consistently reported, and therefore are not considered. Previous investigations by the U.S. Government Accounting Office and Management Sciences for Health suggested that any variation in INCOTERMS constituted a 3% -15% increase over the factory or ex works (EXW) price<sup>8</sup>.



3) All transactions listed in the GPRM with a price of US\$ 0 or appearing as duplications were considered to be either ARV donations or wrongly filed information. Such transactions were removed from the analysis, along with their corresponding purchase volumes.

4) The prices in this report are international transaction prices, and not the prices paid by end-users at country level. End-user prices are often higher than international transaction prices due to tariffs, taxes, transportation costs, and mark-ups. However, in certain instances, end-user prices could be lower than international transaction prices due to subsidies. More information on end-user prices can be found on the Health

Action International website at <http://www.haiweb.org/medicineprices/><sup>12</sup>.

---

\*\* The IQR is a measure of statistical dispersion being equal to the difference between the third and first quartiles

## Abbreviations

International Non-proprietary Name (INN)	Abbreviation
abacavir	ABC
atazanavir	ATV
didanosine	ddI
didanosine enteric-coated	ddI EC
efavirenz	EFV
emtricitabine	FTC
fos-amprenavir	FPV
indinavir	IDV
lamivudine	3TC
lopinavir	LPV
nelfinavir	NFV
nevirapine	NVP
ritonavir	RTV
saquinavir	SQV
stavudine	d4T
tenofovir	TDF
zidovudine	ZDV

Table 1 : Median transaction price of *first-line* ARV medicines for adult treatment per patient per year (US\$/ppy) at a WHO recommended adult defined daily dose (DDD)  
1a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
d4T 30 mg	2	49 (49-51)	45 (38-48)	36 (33-39)	23 (21-27)	19 (19-28)
d4T 40 mg*	2	55 (53-55)	49 (41-55)	39 (34-49)	23 (23-29)	30 (22-55)
3TC 150 mg	2	70 (70-75)	70 (65-79)	60 (53-60)	40 (38-41)	37 (36-38)
NVP 200 mg	2	88 (66-438)	84 (68-436)	63 (60-63)	44 (43-48)	42 (42-49)
3TC+d4T 150+30mg	2	89 (86-99)	88 (81-97)	76 (76-76)	49 (47-64)	53 (49-59)
3TC+d4T 150+40mg*	2	107 (99-107)	95 (87-98)	73 (73-78)	51 (51-60)	51 (43-55)
3TC+NVP+d4T 150+200+30mg	2	153 (121-164)	166 (145-194)	100 (100-120)	91 (83-101)	91 (88-93)
3TC+NVP+d4T 150+200+40mg*	2	159 (126-170)	165 (155-195)	105 (105-121)	80 (80-99)	91 (91-91)
ZDV 300 mg	2	147 (131-212)	141 (128-165)	149 (131-149)	104 (90-109)	100 (100-110)
3TC+ZDV 150+300 mg	2	234 (195-238)	211 (190-238)	152 ((139-179)	120 (113-136)	115 (114-125)
3TC+NVP+ZDV 150+200+300 mg	2	232 (232-250)	156 (155-298)	242 (196-321)	212 (175-248)	162 (154-178)
EFV 200 mg	3	507 (507-550)	507 (501-542)	270 (235-394)	226 (206-254)	207 (185-216)
EFV 600 mg	1	347 (347-376)	347 (347-367)	245 (245-273)	164 (151-198)	147 (145-173)
ABC+3TC+ZDV 300+150+300 mg	2	1629 (1629-1629)	1241 (1241-1241)	1275 (1176-1311)	852 (852-852)	852 (852-852)

\* d4T 40mg x 2/day : not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

## 1b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
d4T 30 mg	2	41 (40-48)	50 (43-60)	39 (32-116)	27 (26-50)	26 (24-30)
d4T 40 mg*	2	45 (44-52)	55 (51-66)	46 (35-526)	32 (30-52)	31 (29-34)
3TC 150 mg	2	71 (70-75)	75 (69-96)	60 (50-186)	45 (40-66)	43 (37-58)
NVP 200 mg	2	103 (87-108)	95 (68-111)	61 (58-81)	50 (47-53)	50 (43-59)
3TC+d4T 150+30mg	2	90 (88-91)	153 (153-153)	77 (73-99)	85 (77-143)	69 (60-91)
3TC+d4T 150+40mg*	2	92 (92-92)	95 (93-99)	83 (79-125)	86 (79-150)	100 (56-100)
3TC+NVP+d4T 150+200+30 mg	2	154 (154-154)	187 (176-207)	147 (132-173)	97 (87-103)	132 (101-151)
3TC+NVP+d4T 150+200+40 mg*	2	160 (160-164)	213 (189-326)	154 (138-206)	95 (82-99)	157 (150-157)
ZDV 300 mg	2	141 (139-198)	212 (180-228)	145 (120-204)	113 (106-120)	113 (105-127)
3TC+ZDV 150+300 mg	2	238 (209-254)	234 (193-254)	177 (157-429)	136 (127-474)	128 (117-153)
3TC+NVP+ZDV 150+200+300 mg	2	303 (303-304)	273 (271-276)	277 (277-277)	182 (182-182)	173 (150-301)
EFV 200 mg	3	469 (469-487)	482 (431-653)	306 (231-507)	206 (205-558)	212 (200-391)
EFV 600 mg	1	347 (347-767)	438 (370-767)	338 (251-664)	218 (179-361)	173 (155-236)
ABC+3TC+ZDV 300+150+300 mg	2	1304 (1304-1311)	3612 (2482-4741)	-	1825 (1825-1825)	3256 (3256-3256)

\* d4T 40mg x 2/day : not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

## 1c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
d4T 30 mg	2	48 (30-93)	41 (39-52)	37 (32-72)	41 (37-73)	37 (30-39)
d4T 40 mg*	2	44 (37-73)	45 (42-54)	42 (35-72)	59 (30-501)	57 (50-501)
3TC 150 mg	2	69 (57-79)	76 (68-81)	71 (54-80)	66 (55-80)	59 (52-66)
NVP 200 mg	2	143 (76-499)	103 (82-177)	72 (61-500)	73 (64-250)	66 (49-120)
3TC+d4T 150+30mg	2	86 (86-86)	86 (86-86)	77 (75-78)	130 (59-201)	53 (53-53)
3TC+d4T 150+40mg*	2	92 (92-92)	92 (92-92)	80 (80-82)	58 (58-58)	-
3TC+NVP+d4T 150+200+30 mg	2	217 (217-217)	196 (193-198)	298 (152-424)	101 (100-102)	86 (84-88)
3TC+NVP+d4T 150+200+40 mg*	2	217 (217-217)	230 (196-209)	460 (228-460)	125 (96-153)	-
ZDV 300 mg	2	1190 (710-1460)	394 (384-410)	159 (126-242)	146 (139-242)	112 (103-130)
3TC+ZDV 150+300 mg	2	255 (169-271)	253 (249-745)	203 (179-1251)	205 (194-271)	183 (131-202)
3TC+NVP+ZDV 150+200+300 mg	2	256 (256-256)	268 (268-268)	311 (282-339)	425 (303-547)	162 (161-178)
EFV 200 mg	3	567 (518-584)	576 (540-597)	409 (392-435)	417 (395-467)	357 (204-384)
EFV 600 mg	1	347 (347-382)	401 (380-432)	292 (273-316)	273 (238-281)	197 (157-227)
ABC+3TC+ZDV 300+150+300 mg	2	-	5872 (5872-5872)	5872 (5872-5872)	-	-

\* d4T 40mg x 2/day : not recommended by WHO (<http://www.who.int/hiv/treatment/en/index.html>)

Table 2: Median transaction price of *second-line* ARV medicines (US\$/ppy) for adult treatment at a WHO recommended adult DDD

## 2a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 300 mg	2	887 (887-887)	887 (887-887)	578 (540-887)	402 (356-436)	335 (314-389)
ddl 100 mg	4	311 (302-311)	311 (308-342)	260 (239-311)	243 (209-310)	231 (189-253)
ddl 200 mg	2	311 (311-350)	311 (218-311)	249 (228-310)	251 (208-310)	242 (232-256)
ddl 400 mg	1	253 (221-253)	288 (288-289)	288 (278-305)	288 (288-295)	288 (286-288)
IDV 400 mg*	4	406 (390-406)	406 (401-406)	422 (406-436)	406 (406-443)	406 (331-446)
LPV+RTV 133+33 mg	6	557 (536-594)	548 (500-607)	587 (500-610)	500 (500-587)	496 (440-500)
LPV+RTV 200+50 mg	4	-	-	500 (500-525)	496 (496-496)	496 (496-569)
NFV 250 mg	10	990 (956-1074)	1005 (927-1093)	1013 (910-1108)	1052 (967-1078)	1316 (1316-1316)
RTV 100 mg**	2	90 (89-306)	92 (84-98)	99 (84-129)	88 (83-125)	85 (83-91)
SQV 200 mg*	10	1108 (1027-1108)	1036 (941-1110)	1048 (999-1083)	1063 (1057-1090)	940 (926-953)
TDF 300mg	1	316 (307-322)	301 (301-310)	219 (208-239)	207 (200-228)	207 (151-208)
FTC+TDF 200+300mg	1	-	362 (362-362)	318 (318-319)	319 (319-319)	319 (251-319)
ATV 150mg*	2	-	-	-	-	-
ATV 200mg*	2	-	-	-	-	-

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as a booster of other protease inhibitors only

### 2b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 300 mg	2	887 (841-919)	954(887-967)	954(921-968)	389 (357-468)	350 (315-431)
ddl 100 mg	4	580 (311-580)	382 (311-1161)	562 (406-1566)	299 (226-565)	236 (210-346)
ddl 200 mg	2	235 (233-235)	249 (187-588)	176 (176-176)	251 (237-401)	437 (233-437)
ddl 400 mg	1	1876 (1119-1941)	507 (213-1424)	507 (507-1807)	1060 (466-1840)	1146 (460-1302)
IDV 400 mg*	4	391 (391-686)	463 (406-696)	696 (433-696)	695 (441-764)	446 (393-1637)
LPV+RTV 133+33 mg	6	4510 (4509-4705)	4468 (3904-5475)	3752 (2269-4468)	1134 (1002-1485)	1170 (1120-1220)
LPV+RTV 200+50 mg	4	-	-	678 (678-678)	775 (500-1015)	1139 (1000-3744)
NFV 250 mg	10	1633 (1620-3466)	2113 (1127-2286)	2113 (1621-2240)	2272 (1188-2284)	1322 (1315-1355)
RTV 100 mg**	2	798 (779-908)	593 (218-700)	885 (635-1006)	740 (551-956)	313 (91-870)
SQV 200 mg*	10	2380 (2379-2390)	2040 (1146-2537)	2167 (1184-2454)	2316 (2216-2414)	3297 (2948-4002)
TDF 300mg	1	279 (253-306)	301 (301-608)	608 (344-1294)	223 (203-245)	208 (184-283)
FTC+TDF 200+300mg	1	-	-	324 (320-360)	411 (357-524)	381 (350-759)
ATV 150mg*	2	-	3753 (3729-3778)	2208 (2208-2208)	4014 (4014-4014)	4315 (4315-4315)
ATV 200mg*	2	-	-	2300 (2300-3157)	4010 (4010-4010)	4351 (4351-4351)

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as a booster of other protease inhibitors only

## 2c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 300 mg	2	887 (841-919)	954(921-968)	798 (644-898)	622 (454-681)	373 (351-391)
ddl 100 mg	4	580 (311-580)	678 (406-1566)	565 (442-621)	908 (485-908)	358 (248-624)
ddl 200 mg	2	235 (233-235)	176 (176-176)	741 (741-741)	232 (225-238)	220 (217-235)
ddl 400 mg	1	1876 (1119-1941)	902 (401-1676)	1130 (827-1823)	1270(802-2749)	642 (289-1199)
IDV 400 mg*	4	391 (391-686)	696 (433-696)	696 (696-746)	471 (471-471)	533 (434-631)
LPV+RTV 133+33 mg	6	4510 (4509-4705)	4608 (4441-5559)	4273 (3163-4490)	1092 (1092-2847)	2798 (2068-2803)
LPV+RTV 200+50 mg	4	-	-	6847 (6847-6847)	4813 (1497-6858)	2605 (1000-4210)
NFV 250 mg	10	1633 (1620-3466)	2113 (1597-2325)	1497 (1135-2744)	1424 (1424-1424)	1848 (1335-2277)
RTV 100 mg**	2	798 (779-908)	870 (600-1238)	774 (533-978)	694 (612-775)	584 (489-679)
SQV 200 mg*	10	2380 (2379-2390)	2544 (2404-2577)	2364 (2229-2848)	3509 (3509-3509)	1542 (953-2117)
TDF 300mg	1	279 (253-306)	234 (139-321)	344(207-1278)	806 (534-1078)	263 (237-300)
FTC+TDF 200+300mg	1	-	-	540 (539-539)	539 (539-539)	470 (446-479)
ATV 150mg*	2	-	3753 (3729-3778)	2208 (2208-2208)	5110 (5110-5110)	5110 (5110-5110)
ATV 200mg*	2	-	-	2300 (2300-3157)	4010 (4010-4010)	4010 (4010-4010)

\* Protease inhibitor to be used boosted with ritonavir

\*\* The dose of ritonavir is given for its use as a booster of other protease inhibitors only

Table 3: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment (*infant weighing 5 kg*) at a WHO recommended paediatric DDD  
3a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	4	191(191-191)	191(191-196)	153(145-191)	117(116-131)	100 (100-107)
ddl 10 mg/ml	8	502(343-502)	313(312-365)	311(184-365)	184(183-216)	368 (362-368)
ddl 25 mg	4	170(170-215)	183(170-262)	170(170-205)	170(170-170)	170 (170-170)
ddl 50 mg	2	0	116(116-128)	116(116-122)	116(116-116)	116 (88-116)
EFV 30 mg/ml	3.25	120(119-120)	118(112-122)	107(107-112)	119(107-119)	117 (115-120)
EFV 50 mg	2	0	90(84-96)	81(81-85)	67(61-83)	59 (59-70)
3TC 10 mg/ml	6	61(44-61)	48(44-61)	32(26-44)	22(22-22)	18 (16-37)
LPV+RTV 80+20 mg/ml	2	139(107-237)	111(100-182)	113(100-446)	100(100-100)	100(100-100)
NFV 50 mg/g	15	1282(1192-1337)	1213(1155-1285)	1145(1144-1280)	805(792-1159)	1479 (1479-1479)
NFV 250 mg	4	396(385-425)	402(371-423)	408(396-441)	421(387-431)	421(387-431)
NVP 10 mg/ml	12	319(319-322)	319(319-347)	58(47-114)	39(36-85)	40 (40-71)
d4T 1 mg/ml	12	219(197-219)	33(33-208)	35(33-36)	33(30-34)	31 (31-51)
ZDV 10 mg/ml	12	155(67-156)	78(66-155)	69(57-75)	40(39-72)	39 (38-75)
3TC+d4T 40+10mg	1.5	-	-	-	27(27-27)	27 (27-27)
3TC+d4T 20+5mg	3	-	-	-	37(37-37)	37 (37-37)
3TC+NVP+d4T 20+35+5 mg	3	-	-	49(49-49)	49(49-54)	49 (49-49)
3TC+NVP+d4T 40+70+10 mg	1.5	-	-	48(48-48)	48(48-50)	48 (48-48)
3TC+d4T 30+6 mg	2	-	-	23(23-24)	27(27-27)	26 (26-26)
3TC+NVP+d4T 30+50+6 mg	2	-	-	29(28-29)	30(27-30)	30(30-30)
3TC+d4T 60+12 mg	1	-	-	-	27(27-27)	26(25-26)
3TC+NVP+d4T 60+100+12 mg	1	-	-	84(84-84)	30(27-30)	28 (27-28)

## 3b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	4	204(191-217)	205(191-206)	204(166-206)	126(106-152)	92 (91-138)
ddl 10 mg/ml	8	307(124-468)	350(309-940)	516(273-809)	402(122-493)	934 (431-978)
ddl 25 mg	4	170(170-170)	260(259-268)	215(196-221)	215(196-221)	238 (196-329)
ddl 50 mg	2	0	0	0	88 (88-109)	88 (88-109)
EFV 30 mg/ml	3.25	255(255-255)	222(205-237)	188(188-188)	120(120-120)	119 (119-119)
EFV 50 mg	2	0	90(90-90)	91(90-143)	80(77-84)	77 (65-84)
3TC 10 mg/ml	6	61(47-66)	52(42-70)	43(32-79)	33(18-61)	44 (22-60)
LPV+RTV 80+20 mg/ml	2	1186(906-1186)	125(113-505)	782(745-890)	200(147-248)	176(146-482)
NFV 50 mg/g	15	1800(1781-1855)	1347(1172-1544)	1399(1383-1407)	1437(800-1437)	1403 (821-1779)
NFV 250 mg	4	757(648-1386)	639(574-905)	845(623-910)	908(569-918)	667 (318-911)
NVP 10 mg/ml	12	131(131-482)	308(139-410)	109(54-316)	82(53-143)	88 (44-131)
d4T 1 mg/ml	12	281(262-428)	291(167-537)	526(87-672)	57(41-526)	44 (44-526)
ZDV 10 mg/ml	12	131(92-166)	107(73-167)	98(61-165)	62(53-70)	57 (39-78)
3TC+d4T 40+10 mg	1.5	-	-	-	-	-
3TC+d4T 20+5 mg	3	-	-	-	-	-
3TC+NVP+d4T 20+35+5 mg	3	-	-	-	49(49-49)	49(49-49)
3TC+NVP+d4T 40+70+10 mg	1.5	-	-	-	-	-
3TC+d4T 30+6 mg	2	-	-	-	-	26 (26-27)
3TC+NVP+d4T 30+50+6 mg	2	-	-	-	-	30 (30-30)
3TC+d4T 60+12 mg	1	-	-	-	-	26 (25-26)
3TC+NVP+d4T 60+100+12 mg	1	-	-	-	27(27-27)	28 (27-30)

## 3c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	4	204(191-217)	205(191-206)	175 (161-190)	160 (153-163)	98 (92-100)
ddl 10 mg/ml	8	307(124-468)	350(309-940)	526(526-526)	1000 (493-1031)	934 (431-978)
ddl 25 mg	4	170(170-170)	260(259-268)	204 (183-219)	248 (219-314)	224 (222-250)
ddl 50 mg	2	-	-	-	-	88 (88-109)
EFV 30 mg/ml	3.25	255(255-255)	222(205-237)	-	188(188-188)	119 (119-119)
EFV 50 mg	2	0	90(90-90)	-	80(77-84)	71 (70-76)
3TC 10 mg/ml	6	61(47-66)	52(42-70)	22 (22-44)	44 (22-44)	44 (44-49)
LPV+RTV 80+20 mg/ml	2	1186(906-1186)	125(113-505)	475 (453-549)	219 (113-485)	176(146-482)
NFV 50 mg/g	15	1800(1781-1855)	1347(1172-1544)	-	-	-
NFV 250 mg	4	757(648-1386)	639(574-905)	599 (454-1097)	569 (569-569)	1936 (1597-1936)
NVP 10 mg/ml	12	131(131-482)	308(139-410)	364 (66-444)	131 (44-350)	263 (44-307)
d4T 1 mg/ml	12	281(262-428)	291(167-537)	44 (44-44)	37(36-39)	33 (32-35)
ZDV 10 mg/ml	12	131(92-166)	107(73-167)	83 (71-153)	88(88-164)	88 (88-88)
3TC+d4T 40+10mg	1.5	-	-	-	-	-
3TC+d4T 20+5mg	3	-	-	-	-	-
3TC+NVP+d4T 20+35+5 mg	3	-	-	-	49(49-49)	49(49-49)
3TC+NVP+d4T 40+70+10 mg	1.5	-	-	-	-	-
3TC+d4T 30+6 mg	2	-	-	-	-	26 (26-27)
3TC+NVP+d4T 30+50+6 mg	2	-	-	-	-	30 (30-30)
3TC+d4T 60+12 mg	1	-	-	-	-	26 (25-26)
3TC+NVP+d4T 60+100+12 mg	1	-	-	-	27(27-27)	28 (27-30)

Table 4: Median transaction price of ARV medicines (US\$/ppy) for paediatric treatment (*infant weighing 10 kg*) at a WHO recommended paediatric DDD

4a) Low-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	10	477(476-510)	191(191-196)	382(361-476)	292(256-329)	251 (251-251)
ddl 10 mg/ml	12	753(514-753)	547(546-551)	467(276-547)	276(275-324)	569 (537-569)
ddl 25 mg	5	213(213-225)	213(213-213)	213(213-257)	213(213-213)	213 (213-213)
ddl 50 mg	3	174(156-195)	175(173-192)	173(173-183)	173(173-174)	173 (143-173)
ddl 100 mg	2	0	0	127(119-155)	76(65-97)	115 (94-155)
ddl 125 mg EC	1	113(105-150)	124(86-131)	86(86-86)	250(250-250)	86(74-99)
EFV 50 mg	4	181(169-186)	169(156-169)	0	133(121-166)	118 (118-133)
EFV 100 mg	2	181(181-181)	178(178-178)	0	0	-
EFV 200 mg	1	169(169-181)	169(167-180)	90(78-131)	75(69-85)	65 (59-69)
3TC 10 mg/ml	10	92(73-102)	80(73-102)	53(44-73)	28(27-50)	29 (27-36)
LPV+RTV 80+20mg/ml	3	200(160-356)	173(165-195)	169(150-669)	150(150-150)	200 (200-200)
LPV+RTV 100+25 mg	3	0	0	0	188(188-188)	188(188-188)
LPV+RTV 133+33 mg	2	190(178-198)	183(167-207)	195(167-217)	250(250-250)	167 (167-167)
NFV 250 mg	6	594(578-638)	604(556-659)	608(549-687)	631(580-647)	633 (539-650)
NVP 10 mg/ml	20	532(532-537)	532(291-578)	97(79-190)	65(59-142)	59 (59-67)
NVP 200 mg	1	44(33-219)	44(33-219)	31(30-31)	22(21-24)	21 (20-22)
d4T 15 mg	2	73(58-102)	60(60-69)	31(18-60)	20(18-20)	18 (18-18)
d4T 20 mg	2	68(62-78)	69(39-69)	31(22-69)	24(22-33)	21 (21-21)
ZDV 10 mg/ml	20	259(112-259)	146(146-292)	146(73-146)	67(65-120)	67 (65-73)
ZDV 100 mg	2	115(115-131)	84(55-121)	59(58-75)	42(40-44)	37 (37-44)
3TC+d4T 150+30mg	1	44(38-49)	43(40-48)	38(38-38)	23(23-23)	26 (24-32)
3TC+NVP+d4T 150+200+30 mg	1	76(60-82)	77(69-91)	50(50-60)	39(39-39)	44 (42-45)
3TC+d4T 20+5 mg	5	0	0	0	61(61-61)	61 (61-61)
3TC+d4T 40+10 mg	3	0	0	0	53(53-53)	53 (53-53)
3TC+NVP+d4T 20+35+5 mg	5	0	0	82(82-82)	82(82-90)	82 (82-82)
3TC+NVP+d4T 40+70+10 mg	3	0	0	96(96-96)	96(96-100)	96 (96-96)
3TC+d4T 30+6 mg	4	0	0	47(46-48)	54(53-54)	52 (51-53)
3TC+NVP+d4T 30+50+6 mg	4	0	0	57(56-59)	60(55-60)	60 (59-61)
3TC+d4T 60+12 mg	2	0	0	0	54(54-54)	51 (50-51)
3TC+NVP+d4T 60+100+12 mg	2	0	0	168(168-168)	60(55-60)	55 (54-55)

### 4b) Lower middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	10	510(476-543)	512(476-514)	511(416-515)	315(266-380)	229 (228-346)
ddl 10 mg/ml	12	460(186-703)	526(463-1411)	1006(205-1267)	670(182-873)	543 (543-543)
ddl 25 mg	5	213(213-213)	325(324-335)	268(246-276)	268(246-276)	121 (121-121)
ddl 50 mg	3	-	-	-	132 (132-163)	132 (132-163)
ddl 100 mg	2	-	-	282(221-310)	131(95-282)	98 (94-111)
ddl 125 mg EC	1	95(95-97)	104(103-106)	146(146-146)	71(71-71)	86 (74-99)
EFV 50 mg	4	-	-	-	161(154-169)	154 (130-169)
EFV 100 mg	2	-	-	-	-	-
EFV 200 mg	1	156(156-176)	179(160-198)	102(77-169)	69(68-186)	71 (65-130)
3TC 10 mg/ml	10	102(78-109)	87(71-117)	71(53-147)	55(29-82)	52 (29-90)
LPV+RTV 80+20mg/ml	3	2373(1813-2373)	251(227-1011)	1173(1117-1335)	300(160-372)	209 (200-297)
LPV+RTV 100+25 mg	3	-	-	-	-	-
LPV+RTV 133+33 mg	2	1504(1157-1540)	1325(191-1791)	1231(745-1489)	511(496-591)	500 (500-534)
NFV 250 mg	6	1136(972-2079)	959(879-1358)	1268(935-1364)	1363(854-1377)	1336 (1326-1345)
NVP 10 mg/ml	20	226(191-808)	514(231-684)	182(89-506)	137(88-239)	67 (59-142)
NVP 200 mg	1	49(38-60)	44(38-60)	30(29-40)	25(24-27)	49 (42-61)
d4T 15 mg	2	60(60-60)	922(702-925)	29(29-29)	29(29-29)	37 (37-41)
d4T 20 mg	2	0	0	0	419(22-815)	37 (37-41)
ZDV 10 mg/ml	20	219(154-277)	146(146-292)	114(93-244)	103(88-117)	73 (66-135)
ZDV 100 mg	2	84(78-121)	115(72-131)	53(50-65)	43(40-48)	119 (110-142)
3TC+d4T 150+30mg	1	45(41-49)	47(44-52)	38(37-49)	71(57-86)	35 (31-46)
3TC+NVP+d4T 150+200+30 mg	1	77(77-77)	190(156-210)	66(66-66)	49(44-51)	55 (50-76)
3TC+d4T 20+5 mg	5	-	-	-	-	61 (61-61)
3TC+d4T 40+10 mg	3	-	-	-	-	55 (53-53)
3TC+NVP+d4T 20+35+5 mg	5	-	-	-	82(82-82)	82 (82-82)
3TC+NVP+d4T 40+70+10 mg	3	-	-	-	-	96 (96-96)
3TC+d4T 30+6 mg	4	-	-	-	-	53 (51-54)
3TC+NVP+d4T 30+50+6 mg	4	-	-	-	-	60 (59-61)
3TC+d4T 60+12 mg	2	-	-	-	-	51 (50-53)
3TC+NVP+d4T 60+100+12 mg	2	-	-	-	55(55-55)	55 (50-76)

## 4c) Upper middle-income countries

INN and strengths	Median transaction price (25th -75th Quartile range) (US\$/ppy)					
	DDD (tablets or capsules)	2004	2005	2006	2007	2008
ABC 20 mg/ml	10	510(476-543)	512(476-514)	511(416-515)	399383-407)	228 (228-228)
ddl 10 mg/ml	12	460(186-703)	526(463-1411)	1006(205-1267)	670(182-873)	543 (543-552)
ddl 25 mg	5	213(213-213)	325(324-335)	268(246-276)	311(284-394)	246 (121-287)
ddl 50 mg	3	-	-	-	192(181-205)	172 (132-177)
ddl 100 mg	2	-	-	282(221-310)	131(95-282)	145 (125-148)
ddl 125 mg EC	1	95(95-97)	104(103-106)	146(146-146)	103(99-105)	94 (93-95)
EFV 50 mg	4	-	-	-	171(163-183)	143 (140-153)
EFV 100 mg	2	-	-	-	-	-
EFV 200 mg	1	156(156-176)	179(160-198)	102(77-169)	137(131-156)	117 (61-125)
3TC 10 mg/ml	10	102(78-109)	87(71-117)	71(53-147)	62(52-73)	56 (36-57)
LPV+RTV 80+20 mg/ml	3	2373(1813-2373)	251(227-1011)	1173(1117-1335)	262(168-602)	176 (171-189)
LPV+RTV 100+25 mg	3	-	-	-	-	250 (250-250)
LPV+RTV 133+33 mg	2	1504(1157-1540)	1325(191-1791)	1231(745-1489)	446(364-1054)	934 (933-994)
NFV 250 mg	6	1136(972-2079)	959(879-1358)	1268(935-1364)	1300(1251-1476)	2904 (813-2904)
NVP 10 mg/ml	20	226(191-808)	514(231-684)	182(89-506)	319(88-552)	67 (66-160)
NVP 200 mg	1	49(38-60)	44(38-60)	30(29-40)	36(28-125)	32 (23-36)
d4T 15 mg	2	60(60-60)	922(702-925)	29(29-29)	33(33-34)	30 (21-31)
d4T 20 mg	2	0	0	0	34(33-73)	31 (21-31)
ZDV 10 mg/ml	20	219(154-277)	146(146-292)	114(93-244)	151(110-259)	135 (62-143)
ZDV 100 mg	2	84(78-121)	115(72-131)	53(50-65)	113 (44-116)	89 (44-90)
3TC+d4T 150+30 mg	1	45(41-49)	47(44-52)	38(37-49)	35(30-85)	26 (26-26)
3TC+NVP+d4T 150+200+30 mg	1	77(77-77)	190(156-210)	66(66-66)	46(42-50)	42 (42-42)
3TC+d4T 20+5 mg	5	-	-	-	248(227-255)	-
3TC+d4T 40+10 mg	3	-	-	-	-	-
3TC+NVP+d4T 20+35+5 mg	5	-	-	-	82(82-82)	82(82-82)
3TC+NVP+d4T 40+70+10 mg	3	-	-	-	-	96 (96-96)
3TC+d4T 30+6 mg	4	-	-	-	53 (53-53)	53 (53-53)
3TC+NVP+d4T 30+50+6 mg	4	-	-	-	-	-
3TC+d4T 60+12 mg	2	-	-	-	54 (54-54)	54 (54-54)
3TC+NVP+d4T 60+100+12 mg	2	-	-	-	-	55 (54-55)

Table 5: Median transaction price (US\$) of smallest unit of *rapid tests*

Product name	Median transaction price (25th -75th Quartile range) (US\$/ppy)				
	2004	2005	2006	2007	2008
Capillus HIV 1/2	1.20 (1.18 - 1.23)	1.29 (1.21 - 1.29)	1.41 (1.38 - 1.45)	1.39 (1.39 - 1.45)	1.39 (1.10 - 1.39)
Clearview Complete HIV 1/2	-	-	-	3.00 (3.00 - 3.00)	3.00 (3.00 - 3.00)
Determine HIV 1/2	0.80 (0.80 - 0.80)	0.80 (0.80 - 0.80)	0.80 (0.80 - 0.80)	0.80 (0.66 - 0.80)	0.80 (0.72 - 0.80)
DoubleCheck Gold HIV 1/2	1.10 (1.00 - 1.20)	1.41 (1.41 - 1.41)	1.41 (1.41 - 1.41)	0.79 (0.79 - 0.79)	0.74 (0.69 - 0.78)
First Response HIV 1.2.0	-	0.67 (0.67 - 0.67)	0.70 (0.70 - 0.70)	0.70 (0.63 - 0.70)	0.65 (0.65 - 0.65)
Genie II HIV 1/2	2.54 (2.46 - 3.08)	2.59 (2.42 - 2.70)	2.53 (2.02 - 2.56)	2.68 (2.46 - 2.90)	2.00 (2.00 - 2.00)
HIV 1/2 Antibody Colloidal Gold	-	0.60 (0.60 - 0.60)	-	0.46 (0.46 - 0.46)	0.46 (0.46 - 0.46)
HIV Tri-dot	1.38 (1.35 - 1.42)	1.33 (1.33 - 1.34)	1.33 (1.32 - 1.36)	1.44 (1.43 - 1.45)	1.44 (1.43 - 1.45)
Immunocombll Bispot HIV 1/2	-	-	-	2.20 (2.20 - 2.20)	1.67 (1.67 - 1.67)
OraQuick HIV 1/2	-	4.00 (4.00 - 4.00)	4.00 (4.00 - 4.00)	4.00 (3.79 - 4.00)	3.50 (3.50 - 3.50)
Retrocheck HIV test	-	0.70 (0.70 - 0.70)	-	0.55 (0.55 - 0.55)	0.55 (0.55 - 0.55)
SD Bioline HIV 1/2 3.0	0.47 (0.47 - 0.47)	0.47 (0.47 - 0.47)	0.80 (0.80 - 0.80)	0.80 (0.80 - 0.80)	0.80 (0.80 - 0.80)
Serodia HIV 1/2	1.30 (1.30 - 1.30)	1.24 (1.23 - 1.24)	1.11 (1.11 - 1.18)	1.18 (1.18 - 1.18)	1.18 (1.18 - 1.18)
Stat-Pak HIV 1/2	-	1.15 (1.15 - 1.15)	0.78 (0.65 - 1.15)	1.35 (0.90 - 1.35)	1.35 (1.24 - 1.35)
Uni-Gold HIV	1.41 (1.36 - 1.43)	1.39 (1.39 - 1.49)	1.61 (1.59 - 1.63)	1.93 (1.68 - 1.93)	1.60 (1.27 - 1.60)

Table 6: Median transaction price of *ELISA and confirmatory tests* in 2007 and 2008 (US\$)

6a) ELISA tests

Product name	Median transaction price (25th -75th Quartile range)	
	2007	2008
Enzygnost Anti-HIV 1/2	0.99 (0.99-0.99)	1.00 (1.00-1.00)
Genedia HIV Ag-Ab	0.33 (0.33-0.33)	0.33 (0.33-0.33)
Genscreen HIV 1/2 V2	0.62 (0.60-0.66)	0.52 (0.52-0.52)
HIV EIA Elisa	0.47 (0.46-0.47)	0.40 (0.40-0.40)
Murex HIV Ag-Ab	0.80 (0.80-1.36)	1.25 (0.94-1.43)
Vironostika HIV Uni-form II	1.01 (0.82-1.07)	1.59 (1.39-1.80)

6b) Confirmatory tests

Product name	Median transaction price (25th -75th Quartile range)	
	2007	2008
HIV BLOT 2.2	11.0 (11.0-11.0)	9.44 (9.44-9.44)
Inno-Lia HIV 1/2	18.5 (18.0-19.8)	14.0 (14.0-14.0)
New LAV Blot	17.5 (17.1-17.7)	13.65 (13.65-13.65)
Pepti-LAV	23.9 (23.9-23.9)	15.75 (15.75-15.75)

Fig. 1a: The price trend for the most commonly used *first-line regimens in low-income countries (LIC)* for adult patients.




Fig. 1b: The price trend for the most commonly used *first-line regimens in lower middle-income countries (LMIC)* for adult patients.




Fig. 1c: The price trend for the most commonly used *first-line regimens in upper middle-income countries (UMIC)* for adult patients.




Fig. 2a: The price trend for the most commonly used *second-line regimens in low-income countries (LIC)* for adult patients.






Fig. 2b: The price trend for the most commonly used *second-line regimens in lower middle-income countries (LMIC)* for adult patients




\* calculated based on the median price of LPV+RTV [133+33] mg in 2004 and 2005, and LPV+RTV [200+50] mg in 2006 and 2007

Fig. 2c: The price trend for the most commonly used *second-line regimens in upper middle-income countries (UMIC)* for adult patients.



\* calculated based on the median price of LPV+RTV [133+33] mg in 2004 and 2005, and LPV+RTV [200+50] mg in 2006 and 2007

Fig. 3a: The price trend for the most commonly used *first-line regimens* for paediatric patients (*infant of 5 kg*)



\* calculated based on the median price of 3TC(10mg/ml), NVP(10mg/ml) and d4T(1mg/ml) from 2004 to 2006, and that of 3TC+NVP+d4T [60+100+12] mg for 2007

Fig. 3b: The price trend for the most commonly used *second-line regimens* for paediatric patients (*infant of 5 kg*)





Fig. 4a: The price trend for the most commonly used *first-line regimens* for paediatric patients (*infant of 10 kg*)



\* calculated based on the median price of 3TC+NVP+d4T [150+200+30mg] from 2004 to 2006 and that of 3TC+NVP+d4T [60+100+12]mg for 2007

Fig. 4b: The price trend for the most commonly used *second-line regimens* for paediatric patients (*infant of 10 kg*)





Figure 5: Number of HIV rapid test (2004 - 2007) (millions)



## Discussion

### *Formulations for adult first-line regimens*

The median price of medicines for adult first-line regimens continued to decrease from 2004 to 2008 in low, lower and upper middle-income countries. Prices for first-line medicines in upper and lower middle-income countries have nearly reached the level of prices paid in low-income countries. Some transactions in upper middle-income countries were even made at a lower price than the median price paid by low-income countries. This was most notable for the d4T-based fixed-dose combination (FDC): 3TC+d4T+NVP (150+30+200mg) (see Table 1).

The median price of the most commonly prescribed FDC: 3TC+NVP+d4T (150+200+300 mg), has dropped by 40.5 % over the last five years (from US\$ 153 in 2004 to US\$ 91 in 2008) in low-income countries, by 14.3% (from US\$ 154 in 2004 to US\$ 132 in 2008) in lower middle-income countries, and by 60.3% (from US\$ 217 in 2004 to US\$ 86 in 2008) in upper middle-income countries (see Table 1 and Figures 1a, 1b, and 1c).

The FDC 3TC+NVP+ZDV (150+200+300 mg) is the second most commonly used FDC in low and middle-income countries. The median price of this FDC has also decreased significantly between 2004 to 2008. It fell by 43.0% in lower middle-income, by 37.0% in upper middle-income countries and by 30.2% in low-income countries (see Table 1, and Figures 1 a, 1b, and 1c). Similar reductions in the median price were observed in all formulations for the first-line regimens, except an ABC-containing FDC: ABC+3TC+ZDV (300+150+300 mg).

### *Formulations for adult second-line regimens*

The majority of medicines used for the second-line regimens also showed a substantial decrease in price between 2004 and 2008. However, the magnitude of price reduction is much more significant for lower middle-income countries than for low-income countries and upper middle-income countries. The largest price reduction was reported for an FDC of protease inhibitors, LPV+ RTV (133+33mg), purchased by lower middle-income countries. The price of this formulation fell from US\$ 4510 in 2004 to US\$ 1021 in 2008, representing a reduction of more than 77%. (see Table 2). Other key medicines used for the second-line regimens, such as TDF (300mg) and ABC (300mg), also showed reductions in price during the same period. Prices for TDF were reduced by 34.5% in low-income countries, by 25.4% in lower middle-income countries, and by 6% in upper middle-income countries. Prices for ABC fell by more than 60% in both low-income and lower middle-income countries, and by 57% in upper middle-income countries (see Tables 2a, 2b, and 2c).

A large price reduction of LPV + RTV, resulted in a significant reduction in the the median treatment cost of the WHO recommended second-line regimen, between 2004 and 2008. The price of this regimen, consisting of ABC, ddl, and [LPV+RTV], decreased by 63,3% (from US\$ 7,273 to US\$ 2,666) in lower middle-income countries and by 50.2% in upper middle countries (from US\$ 7,273 to US\$ 3620). This brings the price paid in middle-income countries to a level that is relatively close to the price paid in low-income countries (US\$ 1,139) in 2008 (see Figures 2a, 2b, 2c). The aggregate median price for a combination of 3TC, [LPV+RTV] and TDF - another WHO preferred treatment regimen<sup>14</sup> - also decreased from US\$ 4,860 to US\$ 1,309 or by 73.0% in lower middle-income countries. The price of this regimen is thus also comparable to the price paid in low-income countries (US\$ 741) in 2008 (Figures 2a, 2b, 2c).

Median prices of other formulations for second-line regimens have been very stable and second-line treatment is still eight to thirteen times more expensive than the first-line treatment in both low and middle-income countries.

### *Paediatric formulations*

The introduction of low-dose FDCs in solid form has enabled a rapid decrease in the cost of treating children, especially very young children (body weight of less than 10 kg) who, in the past, were only able to use liquid formulations. A new low-dose FDC recommended by WHO for paediatric treatment<sup>10</sup>, 3TC+NVP+d4T (60+100+12mg), has become available on the market. The cost of the first-line regimen (FDC consisting of 3TC+NVP+d4T) to treat young children with 5 kg body weight has fallen by 95 % between 2004 and 2008 (from US\$ 599 to US\$ 28) in low-income countries and from US\$ 600 to US\$ 28 in lower and upper middle-income countries. See Tables 3a, 3b, 3c).

Paediatric second-line treatment is still significantly more expensive than first-line treatment in both low and middle-income countries. However, the difference between the low and middle-income countries has become much less pronounced in 2008. In some cases, the median price of the second-line treatment is lower in lower and upper middle-income countries than in low-income countries. In 2008 the treatment costs for young children (at 5 kg weight) using a combination of ABC, ddl, and LPV+RTV was US\$ 370 in low-income countries, US\$ 506 in lower middle-income countries and US\$ 498 in upper middle-income countries (see Figures 4a, 4b, 4c). For older children (at 10 kg weight) the cost was US\$ 631 for low-income countries, US\$ 850 for lower middle-income countries and US\$ 1408 for upper middle-income countries (Figures 4a, 4b). This significant reduction in the cost of second-line treatment for children, especially in lower and upper middle-income countries, is mainly due to the lower price of the key formulation of LPV+RTV which has fallen by 83% (table 3b, 3c).

### *HIV diagnostics*

The median transaction price and volume of HIV diagnostics procured by low and middle-income countries was analysed for fifteen rapid tests during the period from 2004 to 2008 and for six ELISA and five confirmatory tests purchased in 2007 and 2008.

The total volume of rapid tests purchased in the first three quarters of 2008 through the procurement organizations participating in the GRPM was 30.22 million

tests. This is 1.5 times the volume in 2007 (20.52 million tests) (Figure 5). Determine HIV 1/2 has been the most popular test with 51.4 % of the sales volume in 2008, followed by HIV 1/2 Antibody Colloidal Gold (12.4%), Uni-Gold HIV (11.9%), Stat-Pak HIV 1/2 (9.1%), SD Bioline HIV 1/2 3.0 (7.0%), and Capillus HIV 1/2 (6.1%).

The median price of Determine was relatively constant at US\$ 0.80 per test from 2004 to 2008, but the median price of Colloidal Gold dropped by 23.3% between 2005 and 2008 (from US\$ 0.60 to US\$ 0.46 per test). Conversely, other major rapid tests with a market share above 5% such as Uni-Gold, Stat-Pak, SD Bioline, Capillus, showed substantial increases in their median prices of between 16% and 70% compared to the 2004 or 2005 prices (Table 5).

Approximately, 0.695 million ELISA tests were procured through the procurement organizations participating in the GRPM in the three first quarters of 2008. HIV EIA Elisa test, Genscreen HIV 1/2 V2 and Vironostika HIV Uni-form II were the three most popular tests with 23.0%, 20.0% and 19.0 % of the sales volume, respectively. The median prices of ELISA tests were within a range from US\$ 0.33 to US\$1.59 per test (Table 6a).



The number of confirmatory tests, including the Western blot and other new tests, purchased by low- and middle-income countries was very small and amounted to only 7,770 tests in the first three quarters of 2008. Inno-Lia HIV is the leading brand with 77.7% of the total volume purchased and a median price of US\$ 14.0 per test, followed by HIV Blot 2.2 with 7.4% of the sales and a median price of US\$ 9.44 per test.

### Conclusions

The downward trend in the price of ARV medicines seen between 2004 and 2007 continued in 2008 for both adult and paediatric HIV treatment. The median price for the FDC for paediatric first-line regimen has become less than US\$ 30 in 2008 in both low and middle-income countries. The price difference between the low and middle-income countries is now the lowest ever for both adult and paediatric treatments. Second-line regimens also became less expensive, but their cost remained 7 to 30 times higher than that of the least expensive first-line regimen in 2008.

The procurement data on HIV diagnostics in GPRM indicates that the market for HIV serology tests appears to be shifting towards rapid tests and away from ELISA and other confirmatory tests. This is probably due to the expansion of HIV programmes that are underway in many developing countries. It also could be due to the increasing use of rapid test as a second or third laboratory test to confirm HIV diagnosis. Significant improvements in the sensitivity and specificity of the rapid tests in the last few years have made this possible, especially in high HIV prevalence countries.

This summary report is intended to provide the pricing data of key ARVs and HIV diagnostics to governments, non-governmental organizations, donors, international organizations, academia, and individuals or institutions directly involved or interested in the procurement of ARVs in resource-poor settings. Comments and suggestions would be greatly appreciated. Please send comments to Mr Boniface Dongmo Nguimfack at [dongmonguimfackb@who.int](mailto:dongmonguimfackb@who.int).



### References

1. World Bank Group -Data and statistics: Country Classification; Income group. Washington September 2007  
<http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20421402~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html>
2. World Bank Group -Data and statistics: World Bank Atlas Method Washington September 2007  
<http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20452009~menuPK:64133156~pagePK:64133150~piPK:64133175~theSitePK:239419,00.html>
3. "Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS",;: A Joint UNICEF, UNAIDS, WHO, MSF Project. United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS, World Health Organization, Médecins Sans Frontières. Geneva, Switzerland. 2006 (data only).  
<http://mednet2.who.int/sourcesprices/>
4. Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries (10th edition). Campaign for Access to Essential Medicines. Médecins Sans Frontières. Geneva, Switzerland. July 2007 (Revision September 2007).  
[http://www.accessmed-msf.org/fileadmin/user\\_upload/diseases/hiv-aids/Untangling\\_the\\_Web/UTW10\\_RSep\\_horizontal.pdf](http://www.accessmed-msf.org/fileadmin/user_upload/diseases/hiv-aids/Untangling_the_Web/UTW10_RSep_horizontal.pdf)
5. Global HIV/AIDS Epidemic: Selection of Antiretroviral Medications Provided Under US Emergency Plan is Limited. Report to Congressional Requesters. United States Government Accountability Office. January 2005.
6. Purchase Price Report. The Global Fund to Fight AIDS, TB, and Malaria. Geneva, Switzerland. September 2007.  
<http://web.theglobalfund.org/ReportServer/Pages/ReportViewer.aspx?/PRM/Product+Price+Report>
7. AFRO Essential Medicines Price Indicator. World Health Organization Regional Office for Africa (WHO AFRO). Brazzaville, Republic of Congo. December 2003.
8. International Drug Price Indicator Guide, 2006 edition. Guide produced in collaboration with the World Health Organization and supported by the Strategies for Enhancing Access to Medicines (SEAM) Program, which is funded by the Bill & Melinda Gates Foundation.  
<http://erc.msh.org/mainpage.cfm?file=1.0.htm&module=Dmp&language=English>
9. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access: Recommendations for a public health approach, 2006 revision. World Health Organization. Geneva, Switzerland. 2006.

<http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf>

10. Antiretroviral therapy of HIV infection in infants and children: towards universal access: Recommendations for a public health approach, 2006 revision. World Health Organization. Geneva, Switzerland. 2006.

<http://www.who.int/entity/hiv/pub/guidelines/paediatric020907.pdf>

11. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach, 2003 Revision. World Health Organization. Geneva, Switzerland. 2004.

[http://www.who.int/hiv/pub/prev\\_care/en/arvrevision2003en.pdf](http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf)

12. Medicine Prices. Health Action International (HAI) and the World Health Organization Department of Essential Drugs and Medicines Policy published a working draft of a manual to collect and analyse the prices people pay for a selection of important medicines, as well as identifying price components (taxes, mark-ups etc.) and the affordability and availability of key medicines. May 2003.

<http://www.haiweb.org/medicineprices/>

13. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access: Recommendations for a public health approach, 2006 revision. World Health Organization. Geneva, Switzerland. 2006. page 43

<http://www.who.int/hiv/pub/guidelines/adult/en/index.html>

14. Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach - Report of a WHO Working Group Meeting. World Health Organization 2007

[http://www.who.int/hiv/pub/meetingreports/Second\\_Line\\_Antiretroviral.pdf](http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf)

Transaction Prices for Antiretroviral Medicines and  
HIV Diagnostics from 2004 to September 2008

